Crescent Biopharma CFO sells 1,112 shares for taxes

CRESCENT BIOPHARMA, INC.

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. Chief Financial Officer Richard William Scalzo reported an open-market sale of 1,112 ordinary shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations tied to vested restricted stock units granted on December 15, 2025.

The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, solely to cover taxes from the RSU vesting. After this transaction, Scalzo directly holds 20,298 ordinary shares, indicating he retains a substantial equity position in the company.

Insider Trade Summary 10b5-1

Net Seller: 1,112 shares

Net Sell 1 txn

Insider Scalzo Richard William

Role Chief Financial Officer

Sold 1,112 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,112	$17.99	$20K

Holdings After Transaction: Ordinary Shares — 20,298 shares (Direct)

Footnotes (2)

1. F1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Shares sold: 1,112 shares Weighted average sale price: $17.99/share Post-transaction holdings: 20,298 shares +1 more

4 metrics

Shares sold 1,112 shares Ordinary Shares sold on June 22, 2026

Weighted average sale price $17.99/share Average price for the 1,112 shares sold

Post-transaction holdings 20,298 shares Directly owned by CFO after the sale

Sale price range $16.88–$18.86/share Range of prices for multiple sale transactions

Key Terms

restricted stock units, tax withholding obligations, Rule 10b5-1 instruction, weighted average price

4 terms

restricted stock units financial

"in connection with the settlement of restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares automatically sold by the Reporting Person to satisfy tax withholding obligations"

Rule 10b5-1 instruction regulatory

"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Crescent Biopharma (CBIO) disclose in this Form 4 filing?

Crescent Biopharma’s CFO reported selling 1,112 ordinary shares. The sale was an automatic transaction to cover tax withholding on vested restricted stock units and was executed under a pre-arranged Rule 10b5-1 instruction.

Why did Crescent Biopharma (CBIO) CFO sell 1,112 shares?

The shares were sold to satisfy tax withholding obligations. The filing explains they were automatically sold in connection with the settlement of restricted stock units granted on December 15, 2025, solely to cover related tax liabilities.

Was the Crescent Biopharma (CBIO) CFO’s share sale pre-planned?

Yes, the transaction followed a Rule 10b5-1 instruction. The CFO adopted this instruction on February 25, 2026, specifying sales intended only to cover taxes from the vesting of restricted stock units.

How many Crescent Biopharma (CBIO) shares does the CFO hold after this sale?

After the sale, the CFO directly holds 20,298 ordinary shares. This post-transaction balance shows that only a small portion of his total holdings was sold to address tax obligations on vested RSUs.

At what prices were the Crescent Biopharma (CBIO) shares sold in this transaction?

The weighted average sale price was $17.99 per share. The filing notes that multiple trades occurred in a price range from $16.88 to $18.86, and detailed breakdowns are available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scalzo Richard William

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/22/2026		S		1,112(1)	D	$17.99(2)	20,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Richard William Scalzo	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)